A012303 ShortStop-HER2

Breast Cancer

Shortened Duration of Adjuvant Therapy in patients with early-stage HER2+ Breast Cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade.

Key Team Members

Principal Investigator

Steven A. Madden, MD

Research Coordinator

Katharine "Kate" Madden

Accepting Patients

Enrollment Started: September 22, 2025

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

Shortened Duration of Adjuvant Therapy in patients with early-stage HER2+ Breast Cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade.